CN110624091A - 具有降脂溶栓效果的银杏叶复合多酚胶囊及其制备方法 - Google Patents
具有降脂溶栓效果的银杏叶复合多酚胶囊及其制备方法 Download PDFInfo
- Publication number
- CN110624091A CN110624091A CN201911025763.0A CN201911025763A CN110624091A CN 110624091 A CN110624091 A CN 110624091A CN 201911025763 A CN201911025763 A CN 201911025763A CN 110624091 A CN110624091 A CN 110624091A
- Authority
- CN
- China
- Prior art keywords
- enzymolysis
- parts
- weight
- extract
- ginkgo leaf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 37
- 239000002775 capsule Substances 0.000 title claims abstract description 36
- 235000008100 Ginkgo biloba Nutrition 0.000 title claims abstract description 31
- 235000011201 Ginkgo Nutrition 0.000 title claims abstract description 27
- -1 compound polyphenol Chemical class 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000002537 thrombolytic effect Effects 0.000 title claims abstract description 12
- 241000218628 Ginkgo Species 0.000 title claims 9
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 60
- 239000000284 extract Substances 0.000 claims abstract description 53
- 239000000843 powder Substances 0.000 claims abstract description 40
- 239000003921 oil Substances 0.000 claims abstract description 37
- 235000019198 oils Nutrition 0.000 claims abstract description 37
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 35
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 35
- 210000004369 blood Anatomy 0.000 claims abstract description 30
- 239000008280 blood Substances 0.000 claims abstract description 30
- 230000000694 effects Effects 0.000 claims abstract description 24
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 17
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 14
- 230000001603 reducing effect Effects 0.000 claims abstract description 14
- 108010019160 Pancreatin Proteins 0.000 claims abstract description 11
- 229940055695 pancreatin Drugs 0.000 claims abstract description 11
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 claims abstract description 6
- 239000009429 Ginkgo biloba extract Substances 0.000 claims abstract description 6
- 229920001503 Glucan Polymers 0.000 claims abstract description 6
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 6
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 6
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 6
- 235000004347 Perilla Nutrition 0.000 claims abstract description 6
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 6
- 235000019774 Rice Bran oil Nutrition 0.000 claims abstract description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 6
- 244000269722 Thea sinensis Species 0.000 claims abstract description 6
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 6
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 6
- 235000020279 black tea Nutrition 0.000 claims abstract description 6
- 235000008397 ginger Nutrition 0.000 claims abstract description 6
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000020339 pu-erh tea Nutrition 0.000 claims abstract description 6
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 6
- 239000008165 rice bran oil Substances 0.000 claims abstract description 6
- 239000000811 xylitol Substances 0.000 claims abstract description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 6
- 235000010447 xylitol Nutrition 0.000 claims abstract description 6
- 229960002675 xylitol Drugs 0.000 claims abstract description 6
- 241000157835 Gardenia Species 0.000 claims description 58
- 238000003756 stirring Methods 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 238000010438 heat treatment Methods 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 239000008367 deionised water Substances 0.000 claims description 21
- 229910021641 deionized water Inorganic materials 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 19
- 210000002421 cell wall Anatomy 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 17
- 230000035699 permeability Effects 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 15
- 108090000631 Trypsin Proteins 0.000 claims description 12
- 102000004142 Trypsin Human genes 0.000 claims description 12
- 230000001276 controlling effect Effects 0.000 claims description 12
- 238000002386 leaching Methods 0.000 claims description 12
- 239000011259 mixed solution Substances 0.000 claims description 12
- 239000013049 sediment Substances 0.000 claims description 12
- 239000012588 trypsin Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 229940088598 enzyme Drugs 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 230000009849 deactivation Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000001471 micro-filtration Methods 0.000 claims description 9
- 239000012466 permeate Substances 0.000 claims description 9
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- 108010014251 Muramidase Proteins 0.000 claims description 8
- 102000016943 Muramidase Human genes 0.000 claims description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 229960000274 lysozyme Drugs 0.000 claims description 8
- 239000004325 lysozyme Substances 0.000 claims description 8
- 235000010335 lysozyme Nutrition 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000004382 Amylase Substances 0.000 claims description 7
- 108010065511 Amylases Proteins 0.000 claims description 7
- 102000013142 Amylases Human genes 0.000 claims description 7
- 235000019418 amylase Nutrition 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 7
- 239000000287 crude extract Substances 0.000 claims description 7
- 108010059892 Cellulase Proteins 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 6
- 229940106157 cellulase Drugs 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- XRHVZWWRFMCBAZ-UHFFFAOYSA-L Endothal-disodium Chemical compound [Na+].[Na+].C1CC2C(C([O-])=O)C(C(=O)[O-])C1O2 XRHVZWWRFMCBAZ-UHFFFAOYSA-L 0.000 claims description 4
- 239000005909 Kieselgur Substances 0.000 claims description 4
- 108010067035 Pancrelipase Proteins 0.000 claims description 4
- 229940045258 pancrelipase Drugs 0.000 claims description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 4
- 108010059820 Polygalacturonase Proteins 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 3
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical group [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 claims description 3
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 239000012465 retentate Substances 0.000 claims description 3
- 238000001223 reverse osmosis Methods 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 102000019280 Pancreatic lipases Human genes 0.000 claims description 2
- 108050006759 Pancreatic lipases Proteins 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 229940116369 pancreatic lipase Drugs 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 abstract description 22
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 8
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 description 13
- 229920001282 polysaccharide Polymers 0.000 description 13
- 239000005017 polysaccharide Substances 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 239000003925 fat Substances 0.000 description 11
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 9
- 229930003944 flavone Natural products 0.000 description 9
- 150000002212 flavone derivatives Chemical class 0.000 description 9
- 235000011949 flavones Nutrition 0.000 description 9
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 9
- 229930003935 flavonoid Natural products 0.000 description 8
- 235000017173 flavonoids Nutrition 0.000 description 8
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 7
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 7
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 3
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 3
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 3
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 3
- 229940074393 chlorogenic acid Drugs 0.000 description 3
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 3
- 235000001368 chlorogenic acid Nutrition 0.000 description 3
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 101710119636 Trypsin-5 Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有降脂溶栓效果的银杏叶复合多酚胶囊及其制备方法,按重量份计,其包括:银杏叶提取物20‑25份、黑茶多酚5‑8份、生姜粉10‑12份、荷叶粉5‑10份、山楂提取物5‑10份、栀子果油10‑12份、红曲1‑2份、葛根提取物5‑8份、普洱茶3‑5份、酵母葡聚糖3‑5份、紫苏油2‑3份、米糠油1‑2份、胰酶2‑3份、木糖醇5‑8份。其通过具有降糖、降脂功效的组分合理复配,以获得一种适用于高血脂、高血栓、动脉粥样硬化人群,能起到降血脂、活血溶栓、防治动脉粥样硬化、减肥瘦身功效的保健品。
Description
技术领域
本发明涉及营养功能性食品与生物发酵领域。更具体地说,本发明涉及一种具有降脂溶栓效果的银杏叶复合多酚胶囊及其制备方法。
背景技术
血脂是血浆中的中性脂肪(甘油三酯和胆固醇)和类脂(磷脂、糖脂、固醇、类固醇)的总称,广泛存在于人体中。它们是生命细胞的基础代谢必需物质,反映了体内脂类代谢的情况。
与血脂有关的病症及可能病因:高胆固醇血症:遗传、摄取过多的胆固醇和饱和脂肪酸、糖尿病、肾病综合症、甲状腺机能低下、阻塞性肝病和服用利尿剂;高三酸甘油酯症:遗传、饮食、肾病综合症、没有控制好的糖尿病、尿毒症及服用利尿剂、降压药等;偏低的高密度脂蛋白胆固醇:遗传、肥胖、运动不足、抽烟、服用类固醇、降压药等。
高血脂会加速全身动脉粥样硬化,造成动脉被粥样斑块堵塞,引起肾功能衰竭、脑卒中、冠心病、心肌梗死、心脏猝死等病症。此外,高血脂症也是促进高血压、糖耐量异常、糖尿病的一个重要危险因素。
目前,药物对高血脂症、动脉粥样硬化的防治措施主要包括以下几种:通过西药扩张血管、调节血脂、抑制血小板、溶解血栓,但西药多为单化学成分、单途径、单靶点进行治疗,长期大量服用副作用大;采用中医传统方剂进行整体辨证施治,但传统方剂有效成分溶出率低,服用剂量大,效果不明显等,不易进入国际市场。
发明内容
为解决上述技术问题,本发明提供了一种具有降脂溶栓效果的银杏叶复合多酚胶囊及其制备方法,其通过阶段性升温、反复酶解的方式提高葛根提取物中多糖以及黄酮的得率,同时通过采用透性调节液促进栀子果细胞内有效成分得以充分释放,进一步的,上述两者和其他具有降糖、降脂功效的组分合理复配,以获得一种适用于高血脂、高血栓、动脉粥样硬化人群,能起到降血脂、活血溶栓、防治动脉粥样硬化、减肥瘦身功效的保健品。
为了实现根据本发明的这些目的和其它优点,提供了一种具有降脂溶栓效果的银杏叶复合多酚胶囊,按重量份计,其包括:银杏叶提取物20-25份、黑茶多酚5-8份、生姜粉10-12份、荷叶粉5-10份、山楂提取物5-10份、栀子果油10-12份、红曲1-2份、葛根提取物5-8份、普洱茶3-5份、酵母葡聚糖3-5份、紫苏油2-3份、米糠油1-2份、胰酶2-3份、木糖醇5-8份。
优选的,所述胰酶包括胰蛋白酶、胰淀粉酶和胰脂肪酶,且按重量份计,胰蛋白酶:胰淀粉酶:胰脂肪酶=1:1.5:2。
优选的,所述葛根提取物的制备方法包括如下步骤:
S11、取葛根后加入葛根重量5倍的去离子水,并在25℃下浸泡10-12h,取出再用去离子水冲洗2-3遍;
S12、将冲洗后的葛根冷冻干燥,然后粉碎,过40目筛,以获得葛根粉;
S13、取葛根粉以及缓冲液进行混合,且按重量比计,葛根粉:缓冲液=1:(6-8),以获得混合体系,记录混合体系总体积数值,以及将pH值调节为5.5-6.0;再对混合体系进行温度处理,以获得浸提体系;
所述温度处理过程包括:
升温至35-42℃,保温45-60min,再降温至22-27℃,保温25-30min,并记录此时混合体系整体的第一体积数值;按照(总体积-第一体积)*70%补入含有去离子水和缓冲液的第一混合液,且按照重量比计,去离子水:缓冲液=4:1;补入第一混合液后,升温至52-63℃,保温60-75min,再降温至42-55℃,保温30-35min,并记录此时混合体系整体的第二体积数值;按照(总体积-第二体积)*55%补入含有去离子水和缓冲液的第二混合液,且按照重量比计,去离子水:缓冲液=3:1;补入第二混合液后,升温至75-85℃,保温75-85min,再降温至55-65℃,保温35-45min;
S14、对所述浸提体系进行酶解,以获得酶解体系;其中,所述酶解过程包括:
第一次酶解:将浸提体系的pH值调节至8.0-9.0,按浸提体系重量的5%加入胰蛋白酶,充分搅拌,且搅拌的同时升温至30-35℃,保温30-35min后得到第一酶解体系;
第二次酶解:待第一次酶解体系温度降至20-25℃后,再调整其pH值至3.5-4.5,按第一次酶解体系重量的3%加入淀粉酶,充分搅拌,且搅拌的同时升温至40-50℃,保温30-35min后得到第二酶解体系;
第三次酶解:待第二次酶解体系温度降至20-25℃后,再调整其pH值至4.5-5.0,按第二次酶解体系重量的2%加入纤维素酶,充分搅拌,且搅拌的同时升温至25-30℃,保温20-30min后得到第三酶解体系;
S15、灭酶活:待酶解完成后,对获得的第三酶解体系升温至90℃,维持10min,以完成灭酶活过程;
S16、在完成灭酶活后的第三酶解体系中按其重量的3%加入活性炭,搅拌均匀,在65℃下保温65-80min后离心,去沉渣后获得葛根提取物粗提体系;
再将葛根提取物粗提体系经硅藻土过滤,得到葛根提取物清液,且过滤压力控制在0.25-0.35MPa;再在葛根提取物清液中按其重量加入3%的活性炭,静置45-60min,然后离心,去沉渣后获得葛根提取物精提液;
S17、将葛根提取物精提液经过微滤陶瓷膜进行过滤,操作温度控制在55-65℃,以获得微滤膜透过液;再将微滤膜透过液经过卷式超滤膜进行过滤,操作温度控制在55-65℃,以获得超滤膜透过液;再将超滤膜截留液经过卷式高压反渗透膜进行浓缩,除去水分及部分残留无机盐和小分子杂质,控制操作温度在35-40℃,得到葛根提取物浓缩液;
S18、在所述葛根提取物浓缩液中加入其重量10-20%的三氯乙酸,12000rpm条件下离心20min,取沉淀;再通过真空冷冻干燥方法对所述沉淀进行干燥,以获得葛根提取物。
优选的,所述缓冲液为磷酸氢二钠-柠檬酸缓冲液。
优选的,所述步骤S13中,对混合体系进行温度处理的同时进行超声处理,所述超声功率为100-200W,超声处理时间为10-15min。
优选的,所述栀子果油的提取方法包括:
S21、取新鲜栀子果放入水中,于25℃水温下浸泡24-36h后取出,用水冲洗2-3遍,烘干后磨碎,过100目筛,以获得栀子果粉;
S22、取栀子果粉,并加入其重量5-10倍的去离子水,以获得酶解原料,并对所述酶解原料进行酶解;其中,所述酶解过程包括:
第一次酶解:在所述酶解原料中按栀子果粉重量的5%加入胰蛋白酶以及按栀子果粉重量的45-55%加入用于调节细胞膜和/或细胞壁通透性的透性调节液,调节pH值至6.5-7.5,充分搅拌,且搅拌的同时升温至42-45℃,保温30-45min后得到第一酶解体系;所述透性调节液由酸溶液、甘油、氯化钠和溶菌酶组成,且按重量比计,酸溶液:甘油:氯化钠:溶菌酶=1:(0.7-1.0):(0.02-0.05):(0.03-0.06);
第二次酶解:待第一酶解体系温度降至20-25℃后,再调整其pH值至3.5-4.5,按第一体系重量的4%加入果胶酶,充分搅拌,且搅拌的同时升温至50-60℃,保温30-35min后得到第二酶解体系;
第三次酶解:待第二次酶解体系温度降至20-25℃后,再调整其pH值至4.0-5.5,按第二次酶解体系重量的3.5%加入纤维素酶,充分搅拌,且搅拌的同时升温至50-65℃,保温25-35min后得到第三酶解体系;
S23、待步骤S22中的酶解过程完成后,对获得的第三酶解体系升温至85℃,维持10min,以完成灭酶活过程,获得栀子果酶解体系;
S24、在所述栀子果酶解体系中按其重量的3%加入活性炭,搅拌均匀,在65℃下保温65-85min后离心,去沉渣后获得栀子果油粗提液;再将所述栀子果油粗提液经硅藻土过滤,得到栀子果油提取液,且过滤压力为0.3-0.4MPa;再在所述栀子果油提取液中按其重量加入3%的活性炭,静置45-50min后离心,去沉渣;再静置2-3h后取上层油层,即得到所述栀子果油。
还提供一种具有降脂溶栓效果的银杏叶复合多酚胶囊的制备方法,其包括:
S100、按权利要求1中的组分用量称取各组分,充分混匀,将混匀后的混合物置于真空干燥器内干燥,取出粉碎后过筛;
S200、将步骤S100中过筛后的原料填充胶囊,即得所述具有降脂溶栓效果的银杏叶复合多酚胶囊。
本发明至少包括以下有益效果:
本发明提供了一种具有降脂溶栓效果的银杏叶复合多酚胶囊及其制备方法,其通过阶段性升温、反复酶解的方式提高葛根提取物中多糖以及黄酮的得率,同时通过采用透性调节液来调节细胞膜和/或细胞壁透性,提高栀子果细胞壁和/或细胞壁结构被破坏,使其内容的有效成分(如藏花素、黄酮类物质等)得以充分释放,进一步的,上述两者和其他具有降糖、降脂功效的组分合理复配,以获得一种适用于高血脂、高血栓、动脉粥样硬化人群,能起到降血脂、活血溶栓、防治动脉粥样硬化、减肥瘦身功效的保健品。
本发明的其它优点、目标和特征将部分通过下面的说明体现,部分还将通过对本发明的研究和实践而为本领域的技术人员所理解。
具体实施方式
下面结合实例对本发明做进一步的详细说明,以令本领域技术人员参照说明书文字能够据以实施。
应当理解,本文所使用的诸如“具有”、“包含”以及“包括”术语并不配出一个或多个其它元件或其组合的存在或添加。
需要说明的是,下述实施方案中所述试验方法,如无特殊说明,均为常规方法,所述试剂和材料,如无特殊说明,均可从商业途径获得。
<实施例1>
按重量份计,本实施例中的具有降脂溶栓效果的银杏叶复合多酚胶囊包括:银杏叶提取物20份、黑茶多酚5份、生姜粉10份、荷叶粉5份、山楂提取物5份、栀子果油10份、红曲1份、葛根提取物5份、普洱茶4份、酵母葡聚糖3份、紫苏油2份、米糠油1份、胰酶2份、木糖醇5份。其中,所述胰酶包括胰酶含胰蛋白酶、胰淀粉酶和胰脂肪酶,且按重量份计,胰蛋白酶:胰淀粉酶:胰脂肪酶=1:1.5:2。
葛根主要成分是淀粉,此外还含有多糖以及黄酮类化合物(包括大豆(黄豆)甙、大豆甙元、葛根素等),其中,所述多糖、葛根素和其他黄酮了化合物均具有明显的降低血糖、降血脂作用,能降低血清胆固醇,降低油三酯,用于治疗高血糖,高血脂病症,因此,本实施例还提供了一种所述葛根提取物的制备方法,其包括如下步骤:
S11、取葛根后加入葛根重量5倍的去离子水,并在25℃下浸泡10-12h(优选10.5h),取出再用去离子水冲洗2-3遍;
S12、将冲洗后的葛根冷冻干燥,然后粉碎,过40目筛,以获得葛根粉;
S13、取葛根粉以及缓冲液进行混合,且按重量比计,葛根粉:缓冲液=1:(6-8)(优选1:7),以获得混合体系,记录混合体系总体积数值,以及将pH值调节为5.5-6.0;再对混合体系进行温度处理,以获得浸提体系;所述缓冲液为磷酸氢二钠-柠檬酸缓冲液;
所述温度处理过程包括:
升温至35-42℃(优选37℃),保温45-60min(优选50min),再降温至22-27℃(优选25℃),保温25-30min,并记录此时混合体系整体的第一体积数值;按照(总体积-第一体积)*70%补入含有去离子水和缓冲液的第一混合液,且按照重量比计,第一混合液中去离子水:缓冲液=4:1;补入第一混合液后,升温至52-63℃(优选55℃),保温60-75min(优选70min),再降温至42-55℃(优选45℃),保温30-35min,并记录此时混合体系整体的第二体积数值;按照(总体积-第二体积)*55%补入含有去离子水和缓冲液的第二混合液,且按照重量比计,去离子水:缓冲液=3:1;补入第二混合液后,升温至75-85℃(优选80℃),保温75-85min(优选80min),再降温至55-65℃(优选60℃),保温35-45min;
同时,为进一步提高提取效率,对混合体系进行温度处理的同时进行超声处理,所述超声功率为100-200W(优选150W),超声处理时间为10-15min;
S14、对所述浸提体系进行酶解,以获得酶解体系;其中,所述酶解过程包括:
第一次酶解:将浸提体系的pH值调节至8.0-9.0(优选8.5),按浸提体系重量的5%加入胰蛋白酶,充分搅拌,且搅拌的同时升温至30-35℃(优选32℃),保温30-35min后得到第一酶解体系;
第二次酶解:待第一次酶解体系温度降至20-25℃后,再调整其pH值至3.5-4.5(优选4.0),按第一次酶解体系重量的3%加入淀粉酶,充分搅拌,且搅拌的同时升温至40-50℃(优选45℃),保温30-35min后得到第二酶解体系;
第三次酶解:待第二次酶解体系温度降至20-25℃后,再调整其pH值至4.5-5.0(优选4.8),按第二次酶解体系重量的2%加入纤维素酶,充分搅拌,且搅拌的同时升温至25-30℃(优选28℃),保温20-30min后得到第三酶解体系;
S15、灭酶活:待酶解完成后,对获得的第三酶解体系升温至90℃,维持10min,以完成灭酶活过程;
S16、在完成灭酶活后的第三酶解体系中按其重量的3%加入活性炭,搅拌均匀,在65℃下保温65-80min后离心,去沉渣后获得葛根提取物粗提体系;
再将葛根提取物粗提体系经硅藻土过滤,得到葛根提取物清液,且过滤压力控制在0.25-0.35MPa(优选0.3MPa);再在葛根提取物清液中按其重量加入3%的活性炭,静置45-60min,然后离心,去沉渣后获得葛根提取物精提液;
S17、将葛根提取物精提液经过微滤陶瓷膜进行过滤,操作温度控制在55-65℃(优选60℃),以获得微滤膜透过液;再将微滤膜透过液经过卷式超滤膜进行过滤,操作温度控制在55-65℃(优选60℃),以获得超滤膜透过液;再将超滤膜截留液经过卷式高压反渗透膜进行浓缩,除去水分及部分残留无机盐和小分子杂质,控制操作温度在35-40℃(优选37℃),得到葛根提取物浓缩液;
S18、在所述葛根提取物浓缩液中加入其重量10-20%(优选15%)的三氯乙酸,12000rpm条件下离心20min,取沉淀;再通过真空冷冻干燥方法对所述沉淀进行干燥,以获得葛根提取物。
上述步骤中,首先通过阶段性的升温、保温,可使得葛根细胞结构(如细胞壁等)组成在不同的温度变化环境下被反复冲击、破坏,同时,每一升温、保温阶段结束后补充相应比例的水以及缓冲液,由此对水、酸等蒸发后的反应体系进行补偿,使反应体系始终处于较优的浸提环境中,进一步通过胰蛋白酶、淀粉酶分解以及三氯乙酸脱蛋白,以此减少大分子蛋白质含量,以提高多糖和黄酮类化合物的纯度和得率。
此外,栀子果资源丰富、价廉易得、且含有多种功效,已在现代食品工业中发挥越来越重要的中作用、具体的,栀子果中主要含有黄酮类、环烯醚菇类、环烯米酮类等化合物,以及含有藏红花素、果胶、鞣质、多糖、藏红花酸、挥发油等成分,其中,黄酮类物质对高血压等疾病具有辅助治疗作用,可实现降血压、血糖等作用。因此,本实施例中还提供一种栀子果油的提取方法,其包括:
S21、取新鲜栀子果放入水中,于25℃水温下浸泡24-36h后取出,用水冲洗2-3遍,烘干后磨碎,过100目筛,以获得栀子果粉;
S22、取栀子果粉,并加入其重量5-10倍的去离子水,以获得酶解原料,并对所述酶解原料进行酶解;其中,所述酶解过程包括:
第一次酶解:在所述酶解原料中按栀子果粉重量的5%加入胰蛋白酶以及按栀子果粉重量的45-55%加入用于调节细胞膜和/或细胞壁通透性的透性调节液,调节pH值至6.5-7.5(优选为7.0),充分搅拌,且搅拌的同时升温至42-45℃(优选为43.5℃),保温30-45min(优选为35min)后得到第一酶解体系;所述透性调节液由酸溶液、甘油、氯化钠和溶菌酶组成,且按重量比计,酸溶液:甘油:氯化钠:溶菌酶=1:(0.7-1.0):(0.02-0.05):(0.03-0.06)(优选为酸溶液:甘油:氯化钠:溶菌酶=1:0.8:0.03:0.04,且所述酸溶液为柠檬酸溶液);
第二次酶解:待第一酶解体系温度降至20-25℃后,再调整其pH值至3.5-4.5(优选为4.0),按第一体系重量的4%加入果胶酶,充分搅拌,且搅拌的同时升温至50-60℃(优选为55℃),保温30-35min(优选为32min)后得到第二酶解体系;
第三次酶解:待第二次酶解体系温度降至20-25℃后,再调整其pH值至4.0-5.5(优选为5.0),按第二次酶解体系重量的3.5%加入纤维素酶,充分搅拌,且搅拌的同时升温至50-65℃(优选为60℃),保温25-35min(优选为30min)后得到第三酶解体系;
S23、待步骤S22中的酶解过程完成后,对获得的第三酶解体系升温至85℃,维持10min,以完成灭酶活过程,获得栀子果酶解体系;
S24、在所述栀子果酶解体系中按其重量的3%加入活性炭,搅拌均匀,在65℃下保温65-85min(优选为75min)后离心,去沉渣后获得栀子果油粗提液;再将所述栀子果油粗提液经硅藻土过滤,得到栀子果油提取液,且过滤压力为0.3-0.4MPa(优选为0.35Mpa);再在所述栀子果油提取液中按其重量加入3%的活性炭,静置45-50min后离心,去沉渣;再静置2-3h(优选2.5h)后取上层油层,即得到所述栀子果油。
<实施例2>
本实施例与实施例1的不同之处仅在于,按重量份计,本实施例中的具有降脂溶栓效果的银杏叶复合多酚胶囊由以下组分组成:银杏叶提取物25份、黑茶多酚8份、生姜粉12份、荷叶粉10份、山楂提取物10份、栀子果油12份、红曲2份、葛根提取物8份、普洱茶5份、酵母葡聚糖4份、紫苏油3份、米糠油2份、胰酶3份、木糖醇8份。
<实施例3>
本实施例与实施例1的不同之处仅在于,按重量份计,本实施例中的具有降脂溶栓效果的银杏叶复合多酚胶囊由以下组分组成:银杏叶提取物24份、黑茶多酚7份、生姜粉11份、荷叶粉6份、山楂提取物8份、栀子果油10.5份、红曲1.5份、葛根提取物7份、普洱茶4份、酵母葡聚糖4份、紫苏油2.5份、米糠油1.5份、胰酶2.5份、木糖醇6份。
<葛根提取物检测>
先将葛根切片、粉碎至30目得到葛根粉备用;向葛根粉中加入木瓜蛋白酶和Tris-HCL缓冲液恒温酶解5h,将酶解物料投入高压反应釜中,加入水,200r/min搅拌条件下加压提取,提取完毕后过滤,取滤液、滤渣备用;滤液在45℃条件下真空浓缩至原体积的10%,加入无水乙醇,静置待沉淀完全,过滤,收集沉淀物;沉淀物在60℃条件下真空干燥0.5h,粉碎,即得作为对比例1的葛根提取物。再将其与本发明实施例1-3中制备的葛粉提取物进行检测,以获得如表1所示出的提取物外观、多糖含量、多糖得率、总黄酮得率、总黄酮含量和葛根素含量。
表1葛根提取物外观、多糖含量及得率、总黄酮含量及得率、葛根素含量
从表1中可以看出,通过本发明的制备方法制备的葛根提取物中,其外观为黄色或淡黄色粉末,色素含量低,品质高,其次,多糖含量、多糖得率、总黄酮得率、总黄酮含量和葛根素含量相对于对比例1而言,分别提高了103%、50%、61%、76%、100%,以此本发明中的葛根发酵物可通过上述多糖、葛根素以及其他黄酮类化合物发挥降血糖血脂、溶解血栓、防止粥样硬化的功效。
<栀子果油检测结果>
采用申请号201110321487.X(“水酶法提取栀子油的方法”)的专利申请中实施例1所述的方法提取栀子果油,以作为对比例2,将其与通过本发明实施例1-3中的栀子果油提取方法获得的栀子果油进行检测,以获得藏花素、绿原酸、黄酮及栀子苷这几种主要降血糖、血脂有效成分的含量,其结果如表2所示。
表2栀子果油藏花素、绿原酸、黄酮以及栀子苷含量
藏花素(mg/g) | 黄酮(mg/g) | 绿原酸(mg/g) | 栀子苷(mg/g) | |
对比例2 | 1.24±0.31 | 3.51±0.25 | 3.14±0.25 | 3.42±0.37 |
实施例1 | 2.24±0.41 | 6.58±0.44 | 4.15±0.58 | 3.92±0.21 |
实施例2 | 2.39±0.29 | 7.25±0.38 | 4.21±0.13 | 3.82±0.35 |
实施例3 | 2.18±0.11 | 6.95±0.57 | 4.23±0.34 | 4.12±0.50 |
类似的,本发明中通过在不同阶段采用不用的酶及酶解条件对栀子果细胞壁进行充分酶解,使细胞壁中的纤维素、果胶等成分破坏殆尽,同时,酸溶液、甘油、氯化钠、溶菌酶可通过改变细胞壁或细胞膜结构来改变两者的通透性,因此本发明中通过采用调节细胞膜和/或细胞壁通透性的透性调节液来调节细胞膜和/或细胞壁透性,可使得细胞壁和/或细胞壁结构被破坏,使其内容的有效成分(如藏花素、黄酮类物质等)得以充分释放,进一步发挥其降血糖功效。
<降血脂功效评价试验>
选取健康的雄性大鼠240只,编号后在正常环境中适应性饲养2周,自由进食饮水。适应性饲养结束后,随机分为6组,每组20只,分别为空白对照组、高脂模型组、阳性治疗组、高剂量组、中剂量组、低剂量组。除空白对照组外,其余各组均采用高脂饲料。将本发明的银杏叶复合多酚胶囊(以下均为“银杏叶复合多酚胶囊”)以及辛伐他汀配制成相应浓度的溶液,阳性对照组按照50mg/kg bw·d灌胃辛伐他汀溶液,高、中、低剂量组分别按照100mg/kgbw·d、50mg/kg bw·d和25mg/kg bw·d灌胃植物药溶液。其他组灌胃相应体积蒸馏水。治疗期为4周,连续喂养10周后,末次喂养后,禁食不禁水10h,主动脉取血测血清中总胆固醇(TC)、高密度脂蛋白(HDL-C)以及低密度脂蛋白(LDL-C)的浓度,检测结果如表3所示。
表3银杏叶复合多酚胶囊对小鼠血清中TC、HDL以及LDL的影响
由表3可见,低、中、高剂量组大鼠血液中的TC含量相对于模型组显著下降,最多下降28.6%。同时,低、中、高剂量组大鼠血液中的HDL-C含量相对于模型组明显上升,最多可上升49.1%。而HDL-C是抗动脉粥状硬化的血浆脂蛋白,是冠心病的保护因子,因此HDL-C含量的上升有助于改善高血脂高血糖引起的并发症;进一步的,低、中、高剂量组大鼠血液中的LDL-C含量相对于模型组有所下降,而LDL-C携带胆固醇积存于动脉壁上,可引起粥状动脉硬化,服用本发明中的银杏叶复合多酚胶囊后LDL-C下降明显即说明本发明中的银杏叶复合多酚胶囊对防治高血脂冠心病等病症具有良好效果。
<预防粥状动脉硬化功效评价试验>
测试人选:常于体力活动或激动时发病;发作时常有反复呕吐、头痛和血压升高;病情进展迅速,常出现意识障碍、偏瘫和其他神经系统局灶性症状;多有高血压病史;CT应作为首选检查;腰穿脑脊液多含血和压力增高(其中20%左右可不含血)。病例组患者均经头颅CT明确诊断,既往高血压病史(2年-40年)。正常对照组为正常未患病人群,模型组为未服用本发明银杏叶复合多酚胶囊的患者,实验组为服用本发明的银杏叶复合多酚胶囊患者,实验组患者于第1天及第14天早晨空腹抽血化验测定血浆D-2聚体(DDI)含量,检测结果如表4所示。于清晨空腹于前臂静脉采血2mL,并加入2%柠檬酸钠抗凝。将采集的血液在离心机中进行3000rpm离心10min。分离上层血浆运用免疫比浊法测定DDI。仪器选用:ACLTOP700全自动血凝分析仪。
表4银杏叶复合多酚胶囊对血浆DDI含量影响
D-2聚体(DDI)指数的上升,代表血块在血管系统中的形成,是急性血栓的一个敏感的标记物。DDI指数的下降,代表着体内血管的通透性恢复,急性血栓的风险下降。从表4中可以看出,实验组服用本发明的银杏叶复合多酚胶囊14d后,患者DDI指数相对模型组有了明显的下降(最多下降62%),逐渐接近正常值范围,由此可见本发明中的银杏叶复合多酚胶囊可起到预防粥状动脉硬化的功效。
需要说明的是,上述实施例1至4中的技术方案可进行任意组合,且组合后获得的技术方案均属于本发明的保护范围。
综上所述,本发明通过阶段性升温、反复酶解的方式提高葛根提取物中多糖以及黄酮的得率,同时通过采用透性调节液促进栀子果细胞内有效成分得以充分释放,进一步的,上述两者和其他具有降糖、降脂功效的组分合理复配,以获得一种适用于高血脂、高血栓、动脉粥样硬化人群,能起到降血脂、活血溶栓、防治动脉粥样硬化、减肥瘦身功效的保健品。
这里说明的设备数量和处理规模是用来简化本发明的说明的。对本发明的应用、修改和变化对本领域的技术人员来说是显而易见的。
尽管本发明的实施方案已公开如上,但其并不仅仅限于说明书和实施方式中所列运用,它完全可以被适用于各种适合本发明的领域,对于熟悉本领域的人员而言,可容易地实现另外的修改,因此在不背离权利要求及等同范围所限定的一般概念下,本发明并不限于特定的细节和这里示出与描述的实例。
Claims (7)
1.具有降脂溶栓效果的银杏叶复合多酚胶囊,其特征在于,按重量份计,其包括:银杏叶提取物20-25份、黑茶多酚5-8份、生姜粉10-12份、荷叶粉5-10份、山楂提取物5-10份、栀子果油10-12份、红曲1-2份、葛根提取物5-8份、普洱茶3-5份、酵母葡聚糖3-5份、紫苏油2-3份、米糠油1-2份、胰酶2-3份、木糖醇5-8份。
2.如权利要求1所述的银杏叶复合多酚胶囊,其特征在于,所述胰酶包括胰蛋白酶、胰淀粉酶和胰脂肪酶,且按重量份计,胰蛋白酶:胰淀粉酶:胰脂肪酶=1:1.5:2。
3.如权利要求1所述的银杏叶复合多酚胶囊,其特征在于,所述葛根提取物的制备方法包括如下步骤:
S11、取葛根后加入葛根重量5倍的去离子水,并在25℃下浸泡10-12h,取出再用去离子水冲洗2-3遍;
S12、将冲洗后的葛根冷冻干燥,然后粉碎,过40目筛,以获得葛根粉;
S13、取葛根粉以及缓冲液进行混合,且按重量比计,葛根粉:缓冲液=1:(6-8),以获得混合体系,记录混合体系总体积数值,以及将pH值调节为5.5-6.0;再对混合体系进行温度处理,以获得浸提体系;
所述温度处理过程包括:
升温至35-42℃,保温45-60min,再降温至22-27℃,保温25-30min,并记录此时混合体系整体的第一体积数值;按照(总体积-第一体积)*70%补入含有去离子水和缓冲液的第一混合液,且按照重量比计,去离子水:缓冲液=4:1;补入第一混合液后,升温至52-63℃,保温60-75min,再降温至42-55℃,保温30-35min,并记录此时混合体系整体的第二体积数值;按照(总体积-第二体积)*55%补入含有去离子水和缓冲液的第二混合液,且按照重量比计,去离子水:缓冲液=3:1;补入第二混合液后,升温至75-85℃,保温75-85min,再降温至55-65℃,保温35-45min;
S14、对所述浸提体系进行酶解,以获得酶解体系;其中,所述酶解过程包括:
第一次酶解:将浸提体系的pH值调节至8.0-9.0,按浸提体系重量的5%加入胰蛋白酶,充分搅拌,且搅拌的同时升温至30-35℃,保温30-35min后得到第一酶解体系;
第二次酶解:待第一次酶解体系温度降至20-25℃后,再调整其pH值至3.5-4.5,按第一次酶解体系重量的3%加入淀粉酶,充分搅拌,且搅拌的同时升温至40-50℃,保温30-35min后得到第二酶解体系;
第三次酶解:待第二次酶解体系温度降至20-25℃后,再调整其pH值至4.5-5.0,按第二次酶解体系重量的2%加入纤维素酶,充分搅拌,且搅拌的同时升温至25-30℃,保温20-30min后得到第三酶解体系;
S15、灭酶活:待酶解完成后,对获得的第三酶解体系升温至90℃,维持10min,以完成灭酶活过程;
S16、在完成灭酶活后的第三酶解体系中按其重量的3%加入活性炭,搅拌均匀,在65℃下保温65-80min后离心,去沉渣后获得葛根提取物粗提体系;
再将葛根提取物粗提体系经硅藻土过滤,得到葛根提取物清液,且过滤压力控制在0.25-0.35MPa;再在葛根提取物清液中按其重量加入3%的活性炭,静置45-60min,然后离心,去沉渣后获得葛根提取物精提液;
S17、将葛根提取物精提液经过微滤陶瓷膜进行过滤,操作温度控制在55-65℃,以获得微滤膜透过液;再将微滤膜透过液经过卷式超滤膜进行过滤,操作温度控制在55-65℃,以获得超滤膜透过液;再将超滤膜截留液经过卷式高压反渗透膜进行浓缩,除去水分及部分残留无机盐和小分子杂质,控制操作温度在35-40℃,得到葛根提取物浓缩液;
S18、在所述葛根提取物浓缩液中加入其重量10-20%的三氯乙酸,12000rpm条件下离心20min,取沉淀;再通过真空冷冻干燥方法对所述沉淀进行干燥,以获得葛根提取物。
4.如权利要求3所述的银杏叶复合多酚胶囊,其特征在于,所述缓冲液为磷酸氢二钠-柠檬酸缓冲液。
5.如权利要求3所述的银杏叶复合多酚胶囊,其特征在于,所述步骤S13中,对混合体系进行温度处理的同时进行超声处理,所述超声功率为100-200W,超声处理时间为10-15min。
6.如权利要求1所述的银杏叶复合多酚胶囊,其特征在于,所述栀子果油的提取方法包括:
S21、取新鲜栀子果放入水中,于25℃水温下浸泡24-36h后取出,用水冲洗2-3遍,烘干后磨碎,过100目筛,以获得栀子果粉;
S22、取栀子果粉,并加入其重量5-10倍的去离子水,以获得酶解原料,并对所述酶解原料进行酶解;其中,所述酶解过程包括:
第一次酶解:在所述酶解原料中按栀子果粉重量的5%加入胰蛋白酶以及按栀子果粉重量的45-55%加入用于调节细胞膜和/或细胞壁通透性的透性调节液,调节pH值至6.5-7.5,充分搅拌,且搅拌的同时升温至42-45℃,保温30-45min后得到第一酶解体系;所述透性调节液由酸溶液、甘油、氯化钠和溶菌酶组成,且按重量比计,酸溶液:甘油:氯化钠:溶菌酶=1:(0.7-1.0):(0.02-0.05):(0.03-0.06);
第二次酶解:待第一酶解体系温度降至20-25℃后,再调整其pH值至3.5-4.5,按第一体系重量的4%加入果胶酶,充分搅拌,且搅拌的同时升温至50-60℃,保温30-35min后得到第二酶解体系;
第三次酶解:待第二次酶解体系温度降至20-25℃后,再调整其pH值至4.0-5.5,按第二次酶解体系重量的3.5%加入纤维素酶,充分搅拌,且搅拌的同时升温至50-65℃,保温25-35min后得到第三酶解体系;
S23、待步骤S22中的酶解过程完成后,对获得的第三酶解体系升温至85℃,维持10min,以完成灭酶活过程,获得栀子果酶解体系;
S24、在所述栀子果酶解体系中按其重量的3%加入活性炭,搅拌均匀,在65℃下保温65-85min后离心,去沉渣后获得栀子果油粗提液;再将所述栀子果油粗提液经硅藻土过滤,得到栀子果油提取液,且过滤压力为0.3-0.4MPa;再在所述栀子果油提取液中按其重量加入3%的活性炭,静置45-50min后离心,去沉渣;再静置2-3h后取上层油层,即得到所述栀子果油。
7.一种具有降脂溶栓效果的银杏叶复合多酚胶囊的制备方法,其特征在于,包括:
S100、按权利要求1中的组分用量称取各组分,充分混匀,将混匀后的混合物置于真空干燥器内干燥,取出粉碎后过筛;
S200、将步骤S100中过筛后的原料填充胶囊,即得所述具有降脂溶栓效果的银杏叶复合多酚胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911025763.0A CN110624091B (zh) | 2019-10-25 | 2019-10-25 | 具有降脂溶栓效果的银杏叶复合多酚胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911025763.0A CN110624091B (zh) | 2019-10-25 | 2019-10-25 | 具有降脂溶栓效果的银杏叶复合多酚胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110624091A true CN110624091A (zh) | 2019-12-31 |
CN110624091B CN110624091B (zh) | 2021-12-14 |
Family
ID=68977801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911025763.0A Active CN110624091B (zh) | 2019-10-25 | 2019-10-25 | 具有降脂溶栓效果的银杏叶复合多酚胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110624091B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111084850A (zh) * | 2019-10-25 | 2020-05-01 | 国众兴合生物医药科技有限公司 | 治疗高血脂症及冠心病的银杏复合多酚植物药及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1333029A (zh) * | 2000-07-10 | 2002-01-30 | 张孝庆 | 一种治疗心脑血管疾病的药品 |
CN1390594A (zh) * | 2002-07-30 | 2003-01-15 | 成都国嘉药物研究所 | 改善血液循环的混合物 |
CN1539475A (zh) * | 2003-10-27 | 2004-10-27 | 张文高 | 一种防治高脂血症、动脉粥样硬化及相关疾病的天然产物组合物 |
CN1650969A (zh) * | 2004-12-08 | 2005-08-10 | 崔彬 | 一种复方银杏叶山楂药物制剂及其制备方法 |
CN1857475A (zh) * | 2006-04-07 | 2006-11-08 | 毛晓敏 | 预防及治疗心脑血管疾病的组合物及其应用 |
CN103520225A (zh) * | 2013-10-29 | 2014-01-22 | 桂林红会药业有限公司 | 一种银杏叶胶囊及其制备方法 |
CN107412720A (zh) * | 2017-09-15 | 2017-12-01 | 李玉保 | 一种治疗糖尿病的苦瓜多肽复方植物药及其制备方法 |
CN107510836A (zh) * | 2017-09-15 | 2017-12-26 | 李玉保 | 一种治疗糖尿病溃疡的苦瓜多肽药物组合物及其制备方法 |
CN109645464A (zh) * | 2019-01-10 | 2019-04-19 | 蕴彤本草(北京)生物科技有限公司 | 具有活血降脂溶栓和中风康复效果复合营养素及制备方法 |
-
2019
- 2019-10-25 CN CN201911025763.0A patent/CN110624091B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1333029A (zh) * | 2000-07-10 | 2002-01-30 | 张孝庆 | 一种治疗心脑血管疾病的药品 |
CN1390594A (zh) * | 2002-07-30 | 2003-01-15 | 成都国嘉药物研究所 | 改善血液循环的混合物 |
CN1539475A (zh) * | 2003-10-27 | 2004-10-27 | 张文高 | 一种防治高脂血症、动脉粥样硬化及相关疾病的天然产物组合物 |
CN1650969A (zh) * | 2004-12-08 | 2005-08-10 | 崔彬 | 一种复方银杏叶山楂药物制剂及其制备方法 |
CN1857475A (zh) * | 2006-04-07 | 2006-11-08 | 毛晓敏 | 预防及治疗心脑血管疾病的组合物及其应用 |
CN103520225A (zh) * | 2013-10-29 | 2014-01-22 | 桂林红会药业有限公司 | 一种银杏叶胶囊及其制备方法 |
CN107412720A (zh) * | 2017-09-15 | 2017-12-01 | 李玉保 | 一种治疗糖尿病的苦瓜多肽复方植物药及其制备方法 |
CN107510836A (zh) * | 2017-09-15 | 2017-12-26 | 李玉保 | 一种治疗糖尿病溃疡的苦瓜多肽药物组合物及其制备方法 |
CN109645464A (zh) * | 2019-01-10 | 2019-04-19 | 蕴彤本草(北京)生物科技有限公司 | 具有活血降脂溶栓和中风康复效果复合营养素及制备方法 |
Non-Patent Citations (6)
Title |
---|
崔雪生等: "益气活血化淤法在冠心病治疗中的应用", 《泰山医学院学报》 * |
张朝波等: "银曲胶囊调节血脂药效学研究", 《安徽医药》 * |
潘洪平等: "复方黄酮胶囊的降脂作用实验研究", 《广西医学》 * |
覃忠于: "银葛通脉茶的质量标准研究", 《广西中医药》 * |
金晶等: "复方荷叶制剂调节血脂作用的研究", 《江西中医学院学报》 * |
饶秋亮等: "银葛健脑茶对血脂及血液流变学影响的实验研究", 《云南中医中药杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111084850A (zh) * | 2019-10-25 | 2020-05-01 | 国众兴合生物医药科技有限公司 | 治疗高血脂症及冠心病的银杏复合多酚植物药及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110624091B (zh) | 2021-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101102783B (zh) | 黑大豆皮提取物及其提取方法和应用 | |
CN102224879B (zh) | 香菇多肽的制备方法和用途 | |
CN110801024A (zh) | 降低血糖血脂及糖化血红蛋白的多糖复合多肽及制备方法 | |
CN110772630A (zh) | 活化胰岛素受体及调控血糖的复合苦瓜肽口服液及制备方法 | |
CN101664136A (zh) | 一种高活性营养纳豆的制备方法及其应用 | |
JP5452931B2 (ja) | ファセオラス・ブルガリス抽出物、それらの使用、およびそれらを含む組成物 | |
CN110694046A (zh) | 治疗糖尿病及高血脂症的植物药品及制备方法 | |
WO2021078288A1 (zh) | 活化胰岛素及治疗糖尿病的复合苦瓜肽口服药及制备方法 | |
CN109601795A (zh) | 以赶黄草为主要原料的组合物解酒饮料及其制备方法 | |
CN110624091B (zh) | 具有降脂溶栓效果的银杏叶复合多酚胶囊及其制备方法 | |
CN103301321B (zh) | 一种溶栓活性多糖合剂的制作工艺 | |
WO2021078295A1 (zh) | 治疗高脂血症及冠心病的植物药及其制备方法 | |
CN116803295B (zh) | 一种降尿酸组合物及其制备方法 | |
JP4743947B2 (ja) | 脂質代謝改善組成物 | |
CN109846038A (zh) | 一种降三高复方小分子肽功能食品及其制备方法 | |
CN114773495B (zh) | 一种制备具有降糖、降脂功能的茯砖茶茶多糖的方法 | |
CN110800994A (zh) | 降低血糖尿糖及糖化血红蛋白值的复合营养素及制备方法 | |
AU2020103129A4 (en) | The Compounds of Freeze Dried Powder of Cherry and Smilacis Glabrae Rhizoma and the Application in Preparation of Anti-gout Drugs thereof | |
CN107927764A (zh) | 一种含海参提取物与地龙蛋白粉的保健食品及其制备方法 | |
ZA200700559B (en) | Product of vegetal origin comprising proanthocyanidines and its preparation process | |
WO2022205518A1 (zh) | 一种野菠萝多糖的制备方法 | |
CN106723043A (zh) | 一种降三高的食品组合物 | |
CN110694047A (zh) | 治疗肥胖及高血脂症的苦瓜多肽复方植物药及制备方法 | |
CN115414398B (zh) | 板栗提取物及其制备方法以及其在降血糖产品中的应用 | |
CN112841621A (zh) | 利用木耳废渣和果蔬废物的发酵冻干品及其组合物与在高脂血症方面的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |